Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MoST substudy of durvalumab + tremelimumab in advanced cancers without actionable molecular targets
ACTRN12616001019493Phase 2Completed
- Sponsor
- University of Sydney
- Start
- Dec 2016
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of durvalumab and tremelimumab in cancer, sponsored by University of Sydney. Primary endpoint: Progression-free survival at 6 months. Started Dec 2016; status: completed.
02
Drugs
durvalumabtremelimumab
03
Conditions
cancer
Beyond the preview
Go deeper on ACTRN12616001019493.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12616001019493.